2023 World Conference on Lung Cancer (Posters)-EP11.02. Dostarlimab + CT vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC: Asian Subgroup Analyses of the PERLA Trial

EP11.02. Dostarlimab + CT vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC: Asian Subgroup Analyses of the PERLA Trial - PDF(Slides)

Back to course

Pdf Summary

A subgroup analysis of the PERLA trial, conducted in Asian patients with metastatic, non-squamous non-small cell lung cancer (NSCLC), compared the efficacy and safety of dostarlimab CT versus pembrolizumab CT as a first-line treatment. The PERLA trial is a global, randomized, double-blind Phase II study. The analysis found that both treatments showed comparable efficacy in the Asian subgroup. The overall response rate (ORR) was 43% for patients receiving dostarlimab CT and 29% for those receiving pembrolizumab CT. The median progression-free survival (PFS) was 6.9 months for dostarlimab CT and 4.7 months for pembrolizumab CT. The safety results were consistent with the overall population, with no new safety signals identified. There were no significant differences in adverse events between the two treatment groups. The study suggests that dostarlimab could be a treatment option for Asian patients with metastatic non-squamous NSCLC. The results support further investigation of dostarlimab in combination with standard of care treatments and future novel cancer therapies in this population. The study was funded by GSK (NCT04581824) and medical writing support was provided by Fishawack Indicia Ltd, funded by GSK. The authors of the study have disclosed their potential conflicts of interest.

Asset Subtitle

DAE HO LEE

Meta Tag

Speaker DAE HO LEE

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

PERLA trial

Asian patients

metastatic non-squamous NSCLC

first-line treatment

dostarlimab CT

pembrolizumab CT

efficacy

safety

overall response rate

progression-free survival